This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Geron Corporation
11/4/2026
Hello and welcome to the Jaron Corporation third quarter 2026 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to turn the call over to Dawn Schottlandt, SVP, Investor Relations and Corporate Affairs. You may begin.
Dawn Schottlandt, SVP, Investor Relations and Corporate Affairs Good morning, everyone. Welcome to the Jaron Corporation third quarter 2026 earnings conference call. Before we begin, please note that during the course of this presentation and question and answer session, We will be making forward-looking statements regarding future events, performance, plans, expectations, and other projections, including those related to our 2026 financial guidance, our current Ritello commercialization strategy, and related opportunities in the U.S. and the EU, the therapeutic potential of Ritello, other anticipated clinical and commercial events and related timelines, the sufficiency of our financial resources, and other statements on that historical fact. which of course involves risks and uncertainties that could cause actual events, performance, and results to differ materially from those contained in these forward-looking statements. Therefore, I refer you to the risks and uncertainties described in today's earnings release and other heading risk factors in Jeremy's most recent periodic report filed with the FCC which identify important factors that could cause actual results to differ materially from those contained in these forward-looking statements and feature updates to Jerron's risk and uncertainties disclosures, including in his upcoming quarterly report on Form 10-Q. Jerron undertakes no duty or obligations updated forward-looking statements. Joining me on today's call are several members of Jerron's management team, Harout Semerjian, Chief Executive Officer, Ahmed ElNawawi, our Chief Commercial Officer, Dr. Joseph Eid, Executive Vice President, Research and Development and Chief Medical Officer, and Michelle Robertson, our Chief Financial Officer. With that, I'll turn it over to Harout to discuss Jaron's progress in the third quarter.
Thank you, Dawn, and good morning, everyone. We continue to execute our strategy to build a leading hematology company. We're delivering consistent Rytello demand growth, reinforcing our confidence in the low-risk MDS-US commercial opportunity and Rytello's growth trajectory over the next several years. We also initiated a gated commercial launch in targeted European markets that gives us the optionality to scale up Ritello's availability through partnerships. Last week, we announced the discontinuation of the IMPACT-MS trial, evaluating imetal stat and relapsed endorefractory myelofibrosis, following a recommendation by the independent DMC. We believe this is the right course of action for patients and Ford Gerald. In the third quarter, we continue to see increased prescribing from community practices leading to a quarter over quarter demand growth of 10% and net revenue growth of 5% or $60.1 million. This represents a 27% increase in net revenue year over year. This performance keeps us on track to achieve the mid to high end of our full year 2026 net revenue guidance range of $220 million to $240 million and reinforces our confidence that Rightello has a long growth runway in the U.S. This year, we started executing our ex-U.S. go-to-market commercial strategy. focused on addressing unmet patient needs and broadening access to Ritello while prioritizing US price integrity. Recent developments, including the exclusion of orphan drugs like Ritello from the CMS GLOBE model, gives us the opportunity to serve more patients globally. We initiated a gated commercial launch to make Rytello available in targeted European markets beginning with Germany where Rytello is expected to be commercially available by the end of this year. In Europe, our approach enables us to retain strategic control of pricing without having to establish full infrastructure in each market or commit to a large upfront investment. This hybrid model also allows us to remain flexible and open to partnership opportunities. To support our global reach, we recently increased our engagement and presentations at multiple international medical meetings and were encouraged by the interest from hematologists in key markets. We will continue to explore opportunities in other geographies where we believe we can help address the significant unmet need of low-risk MDS patients. As we continue to strengthen our operations, another area of focus for us is financial discipline where our investments are intentional and targeted. Our operating expenses were down 9% year-to-date compared to the prior year, reflecting our continued focus on operational efficiency. This discipline is enabling us to update our full year 2026 total operating expense guidance range from $220 million to $230 million. With $339 million of cash on hand, we have a strong balance sheet to fund our current operations, which gives us flexibility to pursue business development opportunities. With that, I'll turn it over to Nawawi to provide more detail on Rytello's commercial performance and our execution.
You're reading a preview of the GERN Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing